Rachel Anderson

Ms. Rachel Anderson


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Children
Verified
Journal Article
Open access
PDF file
WPWilliam Parker
William Parker
LALauren G. Anderson
Lauren G. Anderson
JJJohn Jones
John Jones
RARachel Anderson
Rachel Anderson
LWLauren Williamson
Lauren Williamson
ZKZacharoula Konsoula Konsoula
Zacharoula Konsoula Konsoula
Based on available data that include approximately 20 lines of evidence from studies in laboratory animal models, observations in humans, correlations in time, and pharmacological/toxicological considerations, it has been concluded without reasonable doubt and with no evidence to the contrary that exposure of susceptible babies and children to acetaminophen (paracetamol) induces many, if not most, cases of autism spectrum disorder (ASD). However, the relative number of cases of ASD that might be induced by acetaminophen has not yet been estimated. Here, we examine a variety of evidence, including the acetaminophen-induced reduction of social awareness in adults, the prevalence of ASD through time, and crude estimates of the relative number of ASD cases induced by acetaminophen during various periods of neurodevelopment. We conclude that the very early postpartum period poses the greatest risk for acetaminophen-induced ASD, and that nearly ubiquitous use of acetaminophen during early development could conceivably be responsible for the induction in the vast majority, perhaps 90% or more, of all cases of ASD. Despite over a decade of accumulating evidence that acetaminophen is harmful for neurodevelopment, numerous studies demonstrate that acetaminophen is frequently administered to children in excess of currently approved amounts and under conditions in which it provides no benefit. Further, studies have failed to demonstrate long-term benefits of acetaminophen for the pediatric population, leaving no valid rationale for continued use of the drug in that population given its risks to neurodevelopment.

23 July 2024 in Life
Verified
Journal Article
Open access
PDF file
JJJohn Jones
John Jones
LWLauren Williamson
Lauren Williamson
ZKZacharoula Konsoula Konsoula
Zacharoula Konsoula Konsoula
RARachel Anderson
Rachel Anderson
KRKate Reissner
Kate Reissner
WPWilliam Parker
William Parker
More than 20 previously reported lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to the aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in silico methods to create an ideal (virtual) population of 120,000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal dataset shows little to no risk of acetaminophen use if the cofactors that create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors that impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in the analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.

4 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JJJohn Jones
John Jones
LWLauren Williamson
Lauren Williamson
ZKZacharoula Konsoula Konsoula
Zacharoula Konsoula Konsoula
RARachel Anderson
Rachel Anderson
KRKate Reissner
Kate Reissner
WPWilliam Parker
William Parker
More than 20 lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations previously indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in-silico methods to create an ideal (virtual) population of 120000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal data set shows little to no risk of acetaminophen use if cofactors which create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors which impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.

9 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JJJohn Jones
John Jones
ZKZacharoula Konsoula Konsoula
Zacharoula Konsoula Konsoula
LWLauren Williamson
Lauren Williamson
RARachel Anderson
Rachel Anderson
SMSusanne Meza-Keuthen
Susanne Meza-Keuthen
WPWilliam Parker
William Parker
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.

1 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MPM Vishnu Patel
M Vishnu Patel
CTCaitlin Travers
Caitlin Travers
PCPaul T Corrigan
Paul T Corrigan
RARachel Anderson
Rachel Anderson
JJJohn Jones
John Jones
WPWilliam Parker
William Parker
Overwhelming evidence shows that exposure of susceptible babies and children to acetaminophen (paracetamol) triggers many if not most cases of autism spectrum disorder, and that oxidative stress causes susceptibility. However, these conclusions have not yet been widely acknowledged or integrated into clinical practice or regulatory guidelines, leaving the continued high prevalence of autism spectrum disorder unchecked. To understand why the conclusions have not been widely accepted, this study conducts systematic analyses of all PubMed-indexed papers with “acetaminophen” and “autism” in any search field. In these papers, statements that failed to promote changes in clinical practice or regulatory guidelines were pervasive. Also pervasive were mishandlings of available evidence, including treating interacting variables as if they are confounding factors (66% of studies affected) and considering too narrow a range of evidence (77% of studies affected). Also present were erroneous criticisms of potentially groundbreaking research, undermining the potential impact of that research. It is hoped that identification of these fundamental problems will lead to widespread acceptance of the evidence that acetaminophen triggers autism spectrum disorder in susceptible babies and children and to subsequent regulatory and clinical changes that will effectively and quickly reduce the induction of autism spectrum disorder.